High throughput bioassay for beta1-adrenoceptor autoantibody detection

Area of Science:

• Cardiology
• Immunology
• Stem Cell Biology

Background:

• Adrenergic beta1-autoantibodies (beta1-AABs) are implicated in cardiomyopathies.
• Immunoapheresis benefits are known, but in-vivo drug development is hindered by a lack of high-throughput autoantibody analytics.
• Traditional bioassays are sensitive but difficult to scale, while immobilized binding partner assays lack scalability.

Purpose of the Study:

• To develop and validate a high-throughput, image-based assay for detecting beta1-AABs.
• To assess the assay's applicability in diagnosing beta1-AAB-related cardiomyopathies.
• To provide a scalable alternative to current diagnostic methods.

Main Methods:

• Development of a high-throughput, image-based assay measuring cardiomyocyte beat rate and contractility.
• Utilized human induced pluripotent stem cell (iPSC)-derived cardiomyocytes.
• Compared results with the classical bioassay using spontaneously beating neonatal rat cardiomyocytes.

Main Results:

• The high-throughput assay successfully detected beta1-AAB activity in biological samples.
• Results closely mirrored the classical bioassay.
• A discrepancy was noted with a control antibody, potentially due to differences in cardiomyocyte species used in the assays.

Conclusions:

• The iPSC-based high-throughput system offers a viable solution for detecting beta1-AABs.
• This assay can overcome sample-size limitations inherent in traditional bioassay diagnostics.
• Enables more scalable and efficient diagnostics for beta1-AAB-associated conditions.